BioNTech SEBNTXNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +39.04% | -19.54% | -2.56% | +102.64% | +22.02% |
| Gross Profit Growth | +45.32% | -27.19% | -22.96% | +167.63% | +28.59% |
| EBITDA Growth | -22.02% | +1.93% | +0.00% | +0.00% | -29.28% |
| Operating Income Growth | -85.64% | -71.76% | +0.00% | +0.00% | -546.67% |
| Net Income Growth | +23.35% | -43.33% | +0.00% | +0.00% | -114.49% |
| EPS Growth | +20.29% | -42.55% | +0.00% | +0.00% | -114.46% |
| EPS Diluted Growth | +17.39% | -41.30% | +0.00% | +0.00% | -114.81% |
| Weighted Average Shares Growth | +0.02% | +1.07% | -0.08% | +1.64% | -0.24% |
| Weighted Average Shares Diluted Growth | +2.03% | -0.30% | -0.08% | +1.64% | -2.21% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -184.79% | -158.91% | +0.00% | -92.49% | +0.00% |
| Free Cash Flow Growth | -217.99% | -152.65% | +0.00% | -56.45% | +0.00% |
| Receivables Growth | -40.36% | -29.47% | -46.65% | +404.96% | -41.59% |
| Inventory Growth | -27.09% | -20.80% | -26.35% | -32.17% | -25.54% |
| Asset Growth | +0.87% | -2.07% | -4.83% | -2.70% | -4.73% |
| Book Value per Share Growth | -3.80% | -5.14% | -5.14% | -4.54% | -3.10% |
| Debt Growth | +20.70% | +16.02% | +23.99% | +5.89% | +0.70% |
| R&D Expense Growth | +10.52% | +5.88% | +3.57% | -12.91% | +2.63% |
| SG&A Expenses Growth | -1.95% | -11.58% | -9.05% | -25.24% | -1.33% |